Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Virology Journal
Published in: Virology Journal 1/2023

Open Access 01-12-2023 | Rabies | Review

Revolutionizing viral disease vaccination: the promising clinical advancements of non-replicating mRNA vaccines

Authors: Xiao Guo, Dongying Liu, Yukai Huang, Youcai Deng, Ying Wang, Jingrui Mao, Yuancheng Zhou, Yongai Xiong, Xinghong Gao

Published in: Virology Journal | Issue 1/2023

Login to get access

Abstract

The mRNA vaccine technology was developed rapidly during the global pandemic of COVID-19. The crucial role of the COVID-19 mRNA vaccine in preventing viral infection also have been beneficial to the exploration and application of other viral mRNA vaccines, especially for non-replication structure mRNA vaccines of viral disease with outstanding research results. Therefore, this review pays attention to the existing mRNA vaccines, which are of great value for candidates for clinical applications in viral diseases. We provide an overview of the optimization of the mRNA vaccine development process as well as the good immune efficacy and safety shown in clinical studies. In addition, we also provide a brief description of the important role of mRNA immunomodulators in the treatment of viral diseases. After that, it will provide a good reference or strategy for research on mRNA vaccines used in clinical medicine with more stable structures, higher translation efficiency, better immune efficacy and safety, shorter production time, and lower production costs than conditional vaccines to be used as preventive or therapeutic strategy for the control of viral diseases in the future.
Literature
1.
To KK-W, Sridhar S, Chiu KH-Y, Hung DL-L, Li X, Hung IF-N, Tam AR, Chung TW-H, Chan JF-W, Zhang AJ-X, et al. Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic. Emerg Microbes Infect. 2021;10(1):507–35.PubMedPubMedCentralCrossRef
2.
Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M, Li Y, Zhu L, Wang N, Lv Z, et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020;369(6499):77–81.PubMedCrossRef
3.
Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, Plested JS, Zhu M, Cloney-Clark S, Zhou H, et al. Phase 1–2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N Engl J Med. 2020;383(24):2320–32.PubMedCrossRef
4.
Sanchez-Felipe L, Vercruysse T, Sharma S, Ma J, Lemmens V, Van Looveren D, Arkalagud Javarappa MP, Boudewijns R, Malengier-Devlies B, Liesenborghs L, et al. A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate. Nature. 2021;590(7845):320–5.PubMedCrossRef
5.
Rawat K, Kumari P, Saha L. COVID-19 vaccine: a recent update in pipeline vaccines, their design and development strategies. Eur J Pharmacol. 2021;892: 173751.PubMedCrossRef
6.
7.
Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics–developing a new class of drugs. Nat Rev Drug Discovery. 2014;13(10):759–80.PubMedCrossRef
8.
Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature. 2001;413(6857):732–8.PubMedCrossRef
9.
Diebold SS, Kaisho T, Hemmi H, Akira S. Reis e Sousa C: Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science. 2004;303(5663):1529–31.PubMedCrossRef
10.
Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, Lipford G, Wagner H, Bauer S. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science. 2004;303(5663):1526–9.PubMedCrossRef
11.
Karikó K, Buckstein M, Ni H, Weissman D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity. 2005;23(2):165–75.PubMedCrossRef
12.
13.
14.
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, et al. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N Engl J Med. 2020;383(27):2603–15.PubMedCrossRef
15.
Mockey M, Gonçalves C, Dupuy FP, Lemoine FM, Pichon C, Midoux P. mRNA transfection of dendritic cells: synergistic effect of ARCA mRNA capping with Poly(A) chains in cis and in trans for a high protein expression level. Biochem Biophys Res Commun. 2006;340(4):1062–8.PubMedCrossRef
16.
Stepinski J, Waddell C, Stolarski R, Darzynkiewicz E, Rhoads RE. Synthesis and properties of mRNAs containing the novel “anti-reverse” cap analogs 7-methyl(3’-O-methyl)GpppG and 7-methyl (3’-deoxy)GpppG. RNA. 2001;7(10):1486–95.PubMedPubMedCentral
17.
Krienke C, Kolb L, Diken E, Streuber M, Kirchhoff S, Bukur T, Akilli-Öztürk Ö, Kranz Lena M, Berger H, Petschenka J, et al. A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis. Science. 2021;371(6525):145–53.PubMedCrossRef
18.
Kumar P, Sweeney TR, Skabkin MA, Skabkina OV, Hellen CUT, Pestova TV. Inhibition of translation by IFIT family members is determined by their ability to interact selectively with the 5’-terminal regions of cap0-, cap1- and 5’ppp- mRNAs. Nucleic Acids Res. 2014;42(5):3228–45.PubMedCrossRef
19.
Pardi N, Secreto AJ, Shan X, Debonera F, Glover J, Yi Y, Muramatsu H, Ni H, Mui BL, Tam YK, et al. Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge. Nat Commun. 2017;8:14630–14630.PubMedPubMedCentralCrossRef
20.
Zarghampoor F, Azarpira N, Khatami SR, Behzad-Behbahani A, Foroughmand AM. Improved translation efficiency of therapeutic mRNA. Gene. 2019;707:231–8.PubMedCrossRef
21.
August A, Attarwala HZ, Himansu S, Kalidindi S, Lu S, Pajon R, Han S, Lecerf JM, Tomassini JE, Hard M, et al. A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus. Nat Med. 2021;27(12):2224–33.PubMedPubMedCentralCrossRef
22.
Aldrich C, Leroux-Roels I, Huang KB, Bica MA, Loeliger E, Schoenborn-Kellenberger O, Walz L, Leroux-Roels G, von Sonnenburg F, Oostvogels L. Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: a phase 1 trial. Vaccine. 2021;39(8):1310–8.PubMedPubMedCentralCrossRef
23.
Kim SC, Sekhon SS, Shin WR, Ahn G, Cho BK, Ahn JY, Kim YH. Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency. Mol Cell Toxicol. 2022;18(1):1–8.PubMedCrossRef
24.
25.
Jackson NAC, Kester KE, Casimiro D, Gurunathan S, DeRosa F. The promise of mRNA vaccines: a biotech and industrial perspective. NPJ Vaccines. 2020;5:11.PubMedPubMedCentralCrossRef
26.
Pelletier J, Sonenberg N. Insertion mutagenesis to increase secondary structure within the 5’ noncoding region of a eukaryotic mRNA reduces translational efficiency. Cell. 1985;40(3):515–26.PubMedCrossRef
27.
28.
Asrani KH, Farelli JD, Stahley MR, Miller RL, Cheng CJ, Subramanian RR, Brown JM. Optimization of mRNA untranslated regions for improved expression of therapeutic mRNA. RNA Biol. 2018;15(6):756–62.PubMedPubMedCentral
29.
30.
31.
Holtkamp S, Kreiter S, Selmi A, Simon P, Koslowski M, Huber C, Türeci O, Sahin U. Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood. 2006;108(13):4009–17.PubMedCrossRef
32.
Kon E, Elia U, Peer D. Principles for designing an optimal mRNA lipid nanoparticle vaccine. Curr Opin Biotechnol. 2022;73:329–36.PubMedCrossRef
33.
Mignone F, Gissi C, Liuni S, Pesole G. Untranslated regions of mRNAs. Genome Biol. 2002;3(3):REVIEWS0004-REVIEWS0004.
34.
Gustafsson C, Govindarajan S, Minshull J. Codon bias and heterologous protein expression. Trends Biotechnol. 2004;22(7):346–53.PubMedCrossRef
35.
Linares-Fernández S, Lacroix C, Exposito JY, Verrier B. Tailoring mRNA vaccine to balance innate/adaptive immune response. Trends Mol Med. 2020;26(3):311–23.PubMedCrossRef
36.
Kudla G, Lipinski L, Caffin F, Helwak A, Zylicz M. High guanine and cytosine content increases mRNA levels in mammalian cells. PLoS Biol. 2006;4(6): e180.PubMedPubMedCentralCrossRef
37.
Schnee M, Vogel AB, Voss D, Petsch B, Baumhof P, Kramps T, Stitz L. An mRNA vaccine encoding rabies virus glycoprotein induces protection against lethal infection in mice and correlates of protection in adult and newborn pigs. PLoS Negl Trop Dis. 2016;10(6):e0004746–e0004746.PubMedPubMedCentralCrossRef
38.
Petsch B, Schnee M, Vogel AB, Lange E, Hoffmann B, Voss D, Schlake T, Thess A, Kallen KJ, Stitz L, et al. Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat Biotechnol. 2012;30(12):1210–6.PubMedCrossRef
39.
Lima SA, Chipman LB, Nicholson AL, Chen YH, Yee BA, Yeo GW, Coller J, Pasquinelli AE. Short poly(A) tails are a conserved feature of highly expressed genes. Nat Struct Mol Biol. 2017;24(12):1057–63.PubMedPubMedCentralCrossRef
40.
Grier AE, Burleigh S, Sahni J, Clough CA, Cardot V, Choe DC, Krutein MC, Rawlings DJ, Jensen MC, Scharenberg AM, et al. pEVL: a linear plasmid for generating mRNA IVT templates with extended encoded poly(a) sequences. Mol Ther Nucleic Acids. 2016;5(4): e306.PubMedPubMedCentralCrossRef
41.
Linares-Fernández S, Moreno J, Lambert E, Mercier-Gouy P, Vachez L, Verrier B, Exposito J-Y. Combining an optimized mRNA template with a double purification process allows strong expression of in vitro transcribed mRNA. Mol Ther Nucleic Acids. 2021;26:945–56.PubMedPubMedCentralCrossRef
42.
Wang X, Lu Z, Gomez A, Hon GC, Yue Y, Han D, Fu Y, Parisien M, Dai Q, Jia G, et al. N6-methyladenosine-dependent regulation of messenger RNA stability. Nature. 2014;505(7481):117–20.PubMedCrossRef
43.
Parr CJC, Wada S, Kotake K, Kameda S, Matsuura S, Sakashita S, Park S, Sugiyama H, Kuang Y, Saito H. N 1-Methylpseudouridine substitution enhances the performance of synthetic mRNA switches in cells. Nucleic Acids Res. 2020;48(6): e35.PubMedPubMedCentralCrossRef
44.
45.
Zhang M, Sun J, Li M, Jin X. Modified mRNA-LNP vaccines confer protection against experimental DENV-2 infection in mice. Mol Therapy Methods Clin Develop. 2020;18:702–12.CrossRef
46.
Karikó K, Muramatsu H, Welsh FA, Ludwig J, Kato H, Akira S, Weissman D. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther. 2008;16(11):1833–40.PubMedCrossRef
47.
Pardi N, Weissman D. Nucleoside modified mRNA vaccines for infectious diseases. Methods Mol Biol (Clifton, NJ). 2017;1499:109–21.CrossRef
48.
Triana-Alonso FJ, Dabrowski M, Wadzack J, Nierhaus KH. Self-coded 3’-extension of run-off transcripts produces aberrant products during in vitro transcription with T7 RNA polymerase. J Biol Chem. 1995;270(11):6298–307.PubMedCrossRef
49.
Karikó K, Muramatsu H, Ludwig J, Weissman D. Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. Nucleic Acids Res. 2011;39(21): e142.PubMedPubMedCentralCrossRef
50.
Weissman D, Pardi N, Muramatsu H, Karikó K. HPLC purification of in vitro transcribed long RNA. Methods Mol Biol (Clifton, NJ). 2013;969:43–54.CrossRef
51.
Baiersdörfer M, Boros G, Muramatsu H, Mahiny A, Vlatkovic I, Sahin U, Karikó K. A facile method for the removal of dsRNA contaminant from in vitro-transcribed mRNA. Mol Ther Nucleic Acids. 2019;15:26–35.PubMedPubMedCentralCrossRef
52.
Borkotoky S, Murali A. The highly efficient T7 RNA polymerase: a wonder macromolecule in biological realm. Int J Biol Macromol. 2018;118(Pt A):49–56.PubMedCrossRef
53.
54.
Cavac E, Ramírez-Tapia LE, Martin CT. High-salt transcription of DNA cotethered with T7 RNA polymerase to beads generates increased yields of highly pure RNA. J Biol Chem. 2021;297(3): 100999.PubMedPubMedCentralCrossRef
55.
M.Miller, Alvizo O, Chng C, Jenne S, Mayo M, Mukherjee A, Sundseth S, Chinthala A, Penfield J, Riggins J et al. An engineered T7 RNA polymerase for efficient co-transcriptional capping with reduced dsRNA byproducts in mRNA synthesis. 2022.
56.
Xia H, Yu B, Jiang Y, Cheng R, Lu X, Wu H, Zhu B. Psychrophilic phage VSW-3 RNA polymerase reduces both terminal and full-length dsRNA byproducts in in vitro transcription. RNA Biol. 2022;19(1):1130–42.PubMedPubMedCentralCrossRef
57.
Wu H, Wei T, Yu B, Cheng R, Huang F, Lu X, Yan Y, Wang X, Liu C, Zhu B. A single mutation attenuates both the transcription termination and RNA-dependent RNA polymerase activity of T7 RNA polymerase. RNA Biol. 2021;18(sup1):451–66.PubMedPubMedCentralCrossRef
58.
59.
Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines—A new era in vaccinology. Nat Rev Drug Discovery. 2018;17(4):261–79.PubMedCrossRef
60.
Pardi N, Tuyishime S, Muramatsu H, Kariko K, Mui BL, Tam YK, Madden TD, Hope MJ, Weissman D. Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. J Control Release: Off J Control Release Soc. 2015;217:345–51.CrossRef
61.
Yin Y, Li X, Ma H, Zhang J, Yu D, Zhao R, Yu S, Nie G, Wang H. In situ transforming RNA nanovaccines from polyethylenimine functionalized graphene oxide hydrogel for durable cancer immunotherapy. Nano Lett. 2021;21(5):2224–31.PubMedCrossRef
62.
Zhang NN, Li XF, Deng YQ, Zhao H, Huang YJ, Yang G, Huang WJ, Gao P, Zhou C, Zhang RR, et al. A thermostable mRNA vaccine against COVID-19. Cell. 2020;182(5):1271-1283.e1216.PubMedPubMedCentralCrossRef
63.
Muramatsu H, Lam K, Bajusz C, Laczkó D, Karikó K, Schreiner P, Martin A, Lutwyche P, Heyes J, Pardi N. Lyophilization provides long-term stability for a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine. Mol Ther. 2022;30(5):1941–51.PubMedPubMedCentralCrossRef
64.
65.
Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19(3):141–54.PubMedCrossRef
66.
Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, Tan KS, Wang DY, Yan Y. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res. 2020;7(1):11.PubMedPubMedCentral
67.
McLean HQ, Grijalva CG, Hanson KE, Zhu Y, Deyoe JE, Meece JK, Halasa NB, Chappell JD, Mellis AM, Reed C et al. Household transmission and clinical features of SARS-CoV-2 infections. Pediatrics 2022;149(3).
68.
Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271-280.e278.PubMedPubMedCentralCrossRef
69.
Walsh EE, Frenck RW Jr, Falsey AR, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Mulligan MJ, Bailey R, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. 2020;383(25):2439–50.PubMedCrossRef
70.
Thomas SJ, Moreira ED Jr, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Polack FP, Zerbini C, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. N Engl J Med. 2021;385(19):1761–73.PubMedCrossRef
71.
Corbett KS, Flynn B, Foulds KE, Francica JR, Boyoglu-Barnum S, Werner AP, Flach B, O’Connell S, Bock KW, Minai M, et al. Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. N Engl J Med. 2020;383(16):1544–55.PubMedCrossRef
72.
Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–16.PubMedCrossRef
73.
Zhang Z, Mateus J, Coelho CH, Dan JM, Moderbacher CR, Gálvez RI, Cortes FH, Grifoni A, Tarke A, Chang J, et al. Humoral and cellular immune memory to four COVID-19 vaccines. Cell. 2022;185(14):2434-2451.e2417.PubMedPubMedCentralCrossRef
74.
Mistry P, Barmania F, Mellet J, Peta K, Strydom A, Viljoen IM, James W, Gordon S, Pepper MS. SARS-CoV-2 variants, vaccines, and host immunity. Front Immunol. 2021;12: 809244.PubMedCrossRef
75.
Kremsner PG, Ahuad Guerrero RA, Arana-Arri E, Aroca Martinez GJ, Bonten M, Chandler R, Corral G, De Block EJL, Ecker L, Gabor JJ, et al. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial. Lancet Infect Dis. 2022;22(3):329–40.PubMedCrossRef
76.
Gebre MS, Rauch S, Roth N, Yu J, Chandrashekar A, Mercado NB, He X, Liu J, McMahan K, Martinot A, et al. Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine. Nature. 2022;601(7893):410–4.PubMedCrossRef
77.
Zhao X, Li D, Ruan W, Chen Z, Zhang R, Zheng A, Qiao S, Zheng X, Zhao Y, Dai L, et al. Effects of a prolonged booster interval on neutralization of omicron variant. N Engl J Med. 2022;386(9):894–6.PubMedCrossRef
78.
Han Y, An Y, Chen Q, Xu K, Liu X, Xu S, Duan H, Vogel AB, Şahin U, Wang Q et al. mRNA vaccines expressing homo-prototype/Omicron and hetero-chimeric RBD-dimers against SARS-CoV-2. Cell Res. 2022:1–4.
79.
80.
Richner JM, Himansu S, Dowd KA, Butler SL, Salazar V, Fox JM, Julander JG, Tang WW, Shresta S, Pierson TC, et al. Modified mRNA vaccines protect against Zika virus infection. Cell. 2017;168(6):1114-1125.e1110.PubMedPubMedCentralCrossRef
81.
Richner JM, Jagger BW, Shan C, Fontes CR, Dowd KA, Cao B, Himansu S, Caine EA, Nunes BTD, Medeiros DBA, et al. Vaccine mediated protection against Zika virus-induced congenital disease. Cell. 2017;170(2):273-283.e212.PubMedPubMedCentralCrossRef
82.
Pierson TC, Xu Q, Nelson S, Oliphant T, Nybakken GE, Fremont DH, Diamond MS. The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. Cell Host Microbe. 2007;1(2):135–45.PubMedPubMedCentralCrossRef
83.
Dowd KA, Pierson TC. Antibody-mediated neutralization of flaviviruses: a reductionist view. Virology. 2011;411(2):306–15.PubMedCrossRef
84.
Roth C, Cantaert T, Colas C, Prot M, Casadémont I, Levillayer L, Thalmensi J, Langlade-Demoyen P, Gerke C, Bahl K, et al. A Modified mRNA vaccine targeting immunodominant NS epitopes protects against dengue virus infection in HLA Class I transgenic mice. Front Immunol. 2019;10:1424.PubMedPubMedCentralCrossRef
85.
86.
De Clercq E. Ebola virus (EBOV) infection: therapeutic strategies. Biochem Pharmacol. 2015;93(1):1–10.PubMedCrossRef
87.
88.
Zawilińska B, Kosz-Vnenchak M. General introduction into the Ebola virus biology and disease. Folia Med Cracov. 2014;54(3):57–65.PubMed
89.
Meyer M, Huang E, Yuzhakov O, Ramanathan P, Ciaramella G, Bukreyev A. Modified mRNA-based vaccines elicit robust immune responses and protect Guinea Pigs from Ebola virus disease. J Infect Dis. 2018;217(3):451–5.PubMedCrossRef
90.
Nachbagauer R, Palese P. Is a universal influenza virus vaccine possible? Annu Rev Med. 2020;71:315–27.PubMedCrossRef
91.
Bahl K, Senn JJ, Yuzhakov O, Bulychev A, Brito LA, Hassett KJ, Laska ME, Smith M, Almarsson Ö, Thompson J, et al. Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses. Mol Ther. 2017;25(6):1316–27.PubMedPubMedCentralCrossRef
92.
Feldman RA, Fuhr R, Smolenov I, Mick Ribeiro A, Panther L, Watson M, Senn JJ, Smith M, Almarsson Ӧ, Pujar HS, et al. mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials. Vaccine. 2019;37(25):3326–34.PubMedCrossRef
93.
Banyard AC, Tordo N. Rabies pathogenesis and immunology. Revue scientifique et technique (International Office of Epizootics). 2018;37(2):323–30.PubMed
94.
95.
Alberer M, Gnad-Vogt U, Hong HS, Mehr KT, Backert L, Finak G, Gottardo R, Bica MA, Garofano A, Koch SD, et al. Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. Lancet (London, England). 2017;390(10101):1511–20.PubMedCrossRef
96.
Stitz L, Vogel A, Schnee M, Voss D, Rauch S, Mutzke T, Ketterer T, Kramps T, Petsch B. A thermostable messenger RNA based vaccine against rabies. PLoS Negl Trop Dis. 2017;11(12):e0006108–e0006108.PubMedPubMedCentralCrossRef
97.
Fanales-Belasio E, Raimondo M, Suligoi B, Buttò S. HIV virology and pathogenetic mechanisms of infection: a brief overview. Annali dell’Istituto superiore di sanita. 2010;46(1):5–14.PubMed
98.
Simon V, Ho DD, Abdool Karim Q. HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet (London, England). 2006;368(9534):489–504.PubMedCrossRef
99.
Khalid K, Padda J, Khedr A, Ismail D, Zubair U, Al-Ewaidat OA, Padda S, Cooper AC, Jean-Charles G. HIV and messenger RNA (mRNA) vaccine. Cureus. 2021;13(7):e16197–e16197.PubMedPubMedCentral
100.
Jacobson JM, Routy J-P, Welles S, DeBenedette M, Tcherepanova I, Angel JB, Asmuth DM, Stein DK, Baril J-G, McKellar M, et al. Dendritic cell immunotherapy for HIV-1 infection using autologous HIV-1 RNA: a randomized, double-blind, placebo-controlled clinical trial. J Acquir Immune Defic Syndr. 2016;72(1):31–8.PubMedPubMedCentralCrossRef
101.
Zhao M, Li M, Zhang Z, Gong T, Sun X. Induction of HIV-1 gag specific immune responses by cationic micelles mediated delivery of gag mRNA. Drug Delivery. 2016;23(7):2596–607.PubMedCrossRef
102.
Sun C, Zuo T, Wen Z. First clinical study of germline-targeting strategy: One step closer to a successful bnAb-based HIV vaccine. Innovation (Cambridge (Mass)) 2023;4(1):100374.
103.
Fortner A, Bucur O. mRNA-based vaccine technology for HIV. Discoveries (Craiova, Romania). 2022;10(2): e150.PubMed
104.
Nowalk A, Green M: Epstein-Barr Virus. Microbiol Spectrum 2016;4(3).
105.
Neves M, Marinho-Dias J, Ribeiro J, Sousa H. Epstein-Barr virus strains and variations: Geographic or disease-specific variants? J Med Virol. 2017;89(3):373–87.PubMedCrossRef
106.
Foster H, Ulasov IV, Cobbs CS. Human cytomegalovirus-mediated immunomodulation: effects on glioblastoma progression. Biochim Biophys Acta. 2017;1868(1):273–6.
107.
Hurt C, Tammaro D. Diagnostic evaluation of mononucleosis-like illnesses. Am J Med. 2007;120(10):911.e911-918.CrossRef
108.
Dioverti MV, Razonable RR: Cytomegalovirus. Microbiol Spectrum 2016;4(4).
109.
Diken M, Kreiter S, Selmi A, Britten CM, Huber C, Türeci Ö, Sahin U. Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation. Gene Ther. 2011;18(7):702–8.PubMedCrossRef
110.
Batich KA, Mitchell DA, Healy P, Herndon JE 2nd, Sampson JH. Once, twice, three times a finding: reproducibility of dendritic cell vaccine trials targeting cytomegalovirus in glioblastoma. Clin Cancer Res: Off J Am Assoc Cancer Res. 2020;26(20):5297–303.CrossRef
111.
John S, Yuzhakov O, Woods A, Deterling J, Hassett K, Shaw CA, Ciaramella G. Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity. Vaccine. 2018;36(12):1689–99.PubMedCrossRef
112.
Kares S, Veijalainen O, Kholová I, Tirkkonen M, Vuento R, Huhtala H, Tuimala V, Mäenpää J, Kujala P. HIGH-RISK HPV testing as the primary screening method in an organized regional screening program for cervical cancer: the value of HPV16 and HPV18 genotyping? APMIS: Acta Pathologica, Microbiologica, et Immunologica Scandinavica. 2019;127(11):710–6.PubMedCrossRef
113.
Salomon N, Selmi A, Grunwitz C, Kong A, Stanganello E, Neumaier J, Petschenka J, Diken M, Kreiter S, Türeci Ö, et al. Local radiotherapy and E7 RNA-LPX vaccination show enhanced therapeutic efficacy in preclinical models of HPV16(+) cancer. Cancer Immunol Immunother: CII. 2022;71(8):1975–88.PubMedCrossRef
114.
115.
Awasthi S, Hook LM, Pardi N, Wang F, Myles A, Cancro MP, Cohen GH, Weissman D, Friedman HM. Nucleoside-modified mRNA encoding HSV-2 glycoproteins C, D, and E prevents clinical and subclinical genital herpes. Sci Immunol. 2019;4(39):eaaw7083.
116.
Awasthi S, Knox JJ, Desmond A, Alameh MG, Gaudette BT, Lubinski JM, Naughton A, Hook LM, Egan KP, Tam YK et al. Trivalent nucleoside-modified mRNA vaccine yields durable memory B cell protection against genital herpes in preclinical models. J Clin Investig. 2021;131(23).
117.
Matucci A, Nencini F, Pratesi S, Maggi E, Vultaggio A. An overview on safety of monoclonal antibodies. Curr Opin Allergy Clin Immunol. 2016;16(6):576–81.PubMedCrossRef
118.
Marston HD, Paules CI, Fauci AS. Monoclonal antibodies for emerging infectious diseases - borrowing from history. N Engl J Med. 2018;378(16):1469–72.PubMedCrossRef
119.
120.
Smith SA, Silva LA, Fox JM, Flyak AI, Kose N, Sapparapu G, Khomandiak S, Ashbrook AW, Kahle KM, Fong RH, et al. Isolation and characterization of broad and ultrapotent human monoclonal antibodies with therapeutic activity against Chikungunya virus. Cell Host Microbe. 2015;18(1):86–95.PubMedPubMedCentralCrossRef
121.
Kose N, Fox JM, Sapparapu G, Bombardi R, Tennekoon RN, de Silva AD, Elbashir SM, Theisen MA, Humphris-Narayanan E, Ciaramella G et al. A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection. Sci Immunol. 2019;4(35).
122.
123.
DeFilippis VR. Chikungunya virus vaccines: platforms, progress, and challenges. Curr Top Microbiol Immunol. 2022;435:81–106.PubMed
124.
125.
Deng YQ, Zhang NN, Zhang YF, Zhong X, Xu S, Qiu HY, Wang TC, Zhao H, Zhou C, Zu SL, et al. Lipid nanoparticle-encapsulated mRNA antibody provides long-term protection against SARS-CoV-2 in mice and hamsters. Cell Res. 2022;32(4):375–82.PubMedPubMedCentralCrossRef
126.
Van Hoecke L, Verbeke R, De Vlieger D, Dewitte H, Roose K, Van Nevel S, Krysko O, Bachert C, Schepens B, Lentacker I, et al. mRNA Encoding a bispecific single domain antibody construct protects against influenza A virus infection in mice. Mol Ther Nucleic Acids. 2020;20:777–87.PubMedPubMedCentralCrossRef
127.
Erasmus JH, Archer J, Fuerte-Stone J, Khandhar AP, Voigt E, Granger B, Bombardi RG, Govero J, Tan Q, Durnell LA, et al. Intramuscular delivery of replicon RNA encoding ZIKV-117 human monoclonal antibody protects against Zika virus Infection. Mol Therapy Methods Clin Develop. 2020;18:402–14.CrossRef
128.
Tiwari PM, Vanover D, Lindsay KE, Bawage SS, Kirschman JL, Bhosle S, Lifland AW, Zurla C, Santangelo PJ. Engineered mRNA-expressed antibodies prevent respiratory syncytial virus infection. Nat Commun. 2018;9(1):3999.PubMedPubMedCentralCrossRef
129.
Hotz C, Wagenaar TR, Gieseke F, Bangari DS, Callahan M, Cao H, Diekmann J, Diken M, Grunwitz C, Hebert A et al. Local delivery of mRNA-encoded cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models. Sci Transl Med. 2021;13(610):eabc7804.
130.
Van Hoecke L, Verbeke R, Dewitte H, Lentacker I, Vermaelen K, Breckpot K, Van Lint S. mRNA in cancer immunotherapy: beyond a source of antigen. Mol Cancer. 2021;20(1):48.PubMedPubMedCentralCrossRef
131.
Seneff S, Nigh G, Kyriakopoulos AM, McCullough PA. Innate immune suppression by SARS-CoV-2 mRNA vaccinations: The role of G-quadruplexes, exosomes, and MicroRNAs. Food Chem Toxicol: Int Publ Bt Ind Biol Res Assoc. 2022;164: 113008.CrossRef
132.
Blakney AK, Ip S, Geall AJ. An update on self-amplifying mRNA vaccine development. Vaccines (Basel) 2021, 9(2).
133.
134.
To KKW, Cho WCS. An overview of rational design of mRNA-based therapeutics and vaccines. Expert Opin Drug Discov. 2021;16(11):1307–17.PubMedCrossRef
135.
Qu L, Yi Z, Shen Y, Lin L, Chen F, Xu Y, Wu Z, Tang H, Zhang X, Tian F, et al. Circular RNA vaccines against SARS-CoV-2 and emerging variants. Cell. 2022;185(10):1728-1744.e1716.PubMedPubMedCentralCrossRef
136.
Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, Harrison EM, Ludden C, Reeve R, Rambaut A, Peacock SJ, et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol. 2021;19(7):409–24.PubMedPubMedCentralCrossRef
137.
De Beuckelaer A, Grooten J, De Koker S. Type I Interferons modulate CD8(+) T cell immunity to mRNA vaccines. Trends Mol Med. 2017;23(3):216–26.PubMedCrossRef
138.
Boettler T, Csernalabics B, Salié H, Luxenburger H, Wischer L, Salimi Alizei E, Zoldan K, Krimmel L, Bronsert P, Schwabenland M, et al. SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis. J Hepatol. 2022;77(3):653–9.PubMedPubMedCentralCrossRef
139.
Banerji A, Wickner PG, Saff R, Stone CA Jr, Robinson LB, Long AA, Wolfson AR, Williams P, Khan DA, Phillips E, et al. mRNA Vaccines to prevent COVID-19 disease and reported allergic reactions: current evidence and suggested approach. J Allergy Clin Immunol Pract. 2021;9(4):1423–37.PubMedCrossRef
140.
van Dam CS, Lede I, Schaar J, Al-Dulaimy M, Rösken R, Smits M. Herpes zoster after COVID vaccination. Int J Infect Diseases: IJID: Off Publ Int Soc Infect Diseases. 2021;111:169–71.
141.
Cui Z, Zeng C, Huang F, Yuan F, Yan J, Zhao Y, Zhou Y, Hankey W, Jin VX, Huang J, et al. Cas13d knockdown of lung protease Ctsl prevents and treats SARS-CoV-2 infection. Nat Chem Biol. 2022;18(10):1056–64.PubMedCrossRef
142.
Yang R, Deng Y, Huang B, Huang L, Lin A, Li Y, Wang W, Liu J, Lu S, Zhan Z, et al. A core-shell structured COVID-19 mRNA vaccine with favorable biodistribution pattern and promising immunity. Signal Transduct Target Ther. 2021;6(1):213.PubMedPubMedCentralCrossRef
143.
August A, Shaw CA, Lee H, Knightly C, Kalidindia S, Chu L, Essink BJ, Seger W, Zaks T, Smolenov I et al. Safety and immunogenicity of an mRNA-based human metapneumovirus and parainfluenza virus type 3 combined vaccine in healthy adults. Open Forum Infect Diseases 2022;9(7):ofac206.
144.
Haranaka M, Baber J, Ogama Y, Yamaji M, Aizawa M, Kogawara O, Scully I, Lagkadinou E, Türeci Ӧ, Şahin U, et al. A randomized study to evaluate safety and immunogenicity of the BNT162b2 COVID-19 vaccine in healthy Japanese adults. Nat Commun. 2021;12(1):7105.PubMedPubMedCentralCrossRef
145.
Follmann D, Janes HE, Buhule OD, Zhou H, Girard B, Marks K, Kotloff K, Desjardins M, Corey L, Neuzil KM, et al. Antinucleocapsid antibodies after SARS-CoV-2 infection in the blinded phase of the randomized, placebo-controlled mRNA-1273 COVID-19 vaccine efficacy clinical trial. Ann Intern Med. 2022;175(9):1258–65.PubMedCrossRef
146.
Gandhi RT, Kwon DS, Macklin EA, Shopis JR, McLean AP, McBrine N, Flynn T, Peter L, Sbrolla A, Kaufmann DE, et al. Immunization of HIV-1-infected persons with autologous dendritic cells transfected with mRNA encoding HIV-1 Gag and Nef: results of a randomized, placebo-controlled clinical trial. J Acquir Immune Defic Syndr. 2016;71(3):246–53.PubMedPubMedCentralCrossRef
147.
de Jong W, Aerts J, Allard S, Brander C, Buyze J, Florence E, van Gorp E, Vanham G, Leal L, Mothe B, et al. iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy. Trials. 2019;20(1):361.PubMedPubMedCentralCrossRef
Metadata
Title
Revolutionizing viral disease vaccination: the promising clinical advancements of non-replicating mRNA vaccines
Authors
Xiao Guo
Dongying Liu
Yukai Huang
Youcai Deng
Ying Wang
Jingrui Mao
Yuancheng Zhou
Yongai Xiong
Xinghong Gao
Publication date
01-12-2023
Publisher
BioMed Central
Keyword
Rabies
Published in
Virology Journal / Issue 1/2023
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/s12985-023-02023-0

Other articles of this Issue 1/2023

Virology Journal 1/2023 Go to the issue

Research

Host sex disparity and viral genotype dependence of the glycosylation level of small Hepatitis B surface protein in patients with HBeAg-positive chronic Hepatitis B

Research

Genome characteristics of atypical porcine pestivirus from abortion cases in Shandong Province, China

Research

Clinical characteristics of abruptly increased paediatric patients with Omicron BF.7 or BA.5.2 in Beijing

Research

Epidemiology and clinical severity of the serotypes of human parainfluenza virus in children with acute respiratory infection

Research

Systematic levels of IL-29 and microRNA185-5p were not associated with severe COVID-19 in the Iranian population

Methodology

A full genome tiling array enhanced the inspection and quarantine of SARS-CoV-2
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits